Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB1 | P46663 | 5/20 | 0.33 |
| ▸ | BACE1 | P56817 | 2/20 | 0.33 |
| ▸ | JAK1 | P23458 | 2/20 | 0.32 |
| ▸ | JAK3 | P52333 | 2/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | BRAF | P15056 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
| ▸ | RAF1 | P04049 | 4/20 | 0.31 |
| ▸ | WNT3A | P56704 | 1/20 | 0.31 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.30 |
| ▸ | MPL | P40238 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2809213 | 0.92 | JAK1 (0.34) | BDKRB1JAK1JAK3JAK2BRAF | |
| SCHEMBL185363 | 0.91 | FAAH (0.31) | JAK1JAK3JAK2PTGS2MAP4K1 | |
| SCHEMBL2808302 | 0.86 | BACE1 (0.33) | BDKRB1BACE1RAF1CNR2PDE10A | |
| SCHEMBL2807707 | 0.86 | MAPK3 (0.36) | BDKRB1BACE1BRAFRAF1WNT3A | |
| SCHEMBL2811232 | 0.84 | BRAF (0.36) | BDKRB1BRAFMPL | |
| SCHEMBL2806520 | 0.84 | BDKRB1 (0.35) | BDKRB1BACE1JAK1JAK3PTGS2 | |
| SCHEMBL186120 | 0.82 | JAK1 (0.34) | JAK1JAK3JAK2PTGS2MAP4K1 | |
| SCHEMBL2804889 | 0.81 | MAPK9 (0.36) | BDKRB1JAK3JAK2BRAF | |
| SCHEMBL13128563 | 0.79 | BDKRB1 (0.35) | BDKRB1BACE1BRAFPTGS2RAF1 | |
| Hydrochloric Acid SCHEMBL2806189 | 0.78 | BDKRB1 (0.34) | BDKRB1BACE1BRAFPTGS2RAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130131075-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-05-23 | — | — | US | disclosed |
| US-20100240669-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131075-A1 | NEW COMPOUNDS | ADORA1, H1-10, P2RY11 | BDKRB1 289/4885BACE1 2127/4885JAK1 936/4885 |
| US-20100240669-A1 | NEW COMPOUNDS | ADORA1, H1-10, P2RY11 | BDKRB1 289/4885BACE1 2127/4885JAK1 936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.